Management
Martin D. Williams, President and Chief Executive Officer
Martin has almost two and a half decades of experience of building companies, developing, commercializing and partnering new products in the global biopharmaceutical business. He has closed more than $3 billion worth of corporate transactions, including numerous partnerships, M&A, private financings and public offerings. Prior to joining Tokai, Martin was chief business officer at Dicerna Pharmaceuticals, a venture-backed company focused on oncology, where he closed a $1.4 billion oncology partnership with Kyowa Hakko Kirin. Prior to his tenure at Dicerna, Martin was chief business officer at Synta Pharmaceuticals, with responsibility for corporate development, sales and marketing, corporate communications and medical affairs. While there, he successfully completed the company's IPO in 2007 and negotiated a $1 billion collaboration with GlaxoSmithKline for its lead oncology product. Prior to joining Synta, Martin held leadership positions at a variety of other public and privately held biopharmaceutical companies. He also directed the development and commercialization of several flagship brands for Glaxo, Hofmann-La Roche and Wyeth. These brands include several blockbusters, such as Glaxo's Zantac and Zofran; Hoffmann La-Roche's Xenical; and Wyeth's Zosyn/Tazocin.
Martin holds an M.B.A. from Harvard Business School, an M.S. from the University of Manchester, England, and a B.A. in biology from the University of Humberside in Hull, England.
Jodie Morrison, Chief Operating Officer and Vice President of Clinical Affairs
Jodie has almost 15 years of development experience in multiple therapeutic areas including oncology, urology, women's health, cardiac anesthesiology/surgery, allergy, immunology, neurology/neurosurgery and transplant surgery. Prior to joining Tokai, Jodie was director of clinical operations and medical affairs at Dyax Corporation. While at Dyax, she built the clinical affairs department and oversaw both clinical and medical affairs on the Kalbitor® program for hereditary angioedema and the DX-88 program for cardiothoracic surgery. Previously, Jodie held clinical management positions at both Curis, Inc. and at Diacrin, Inc. Prior to focusing her career in clinical and medical affairs, she worked in the Cell Transplantation Laboratory at Diacrin, Inc.
Jodie holds a B.A. in neuroscience from Mount Holyoke College, her clinical research certification from Boston University School of Medicine and received her business training through the Greater Boston Executive Program at the Massachusetts Institute of Technology Sloan School of Management.
Susan Stewart, Senior Vice President of Regulatory Affairs, Quality and Compliance
Sue has more than 20 years of regulatory affairs and quality assurance experience in the development and commercialization of a broad range of drugs, biologics and devices intended to treat conditions considered unmet medical needs. Prior to joining Tokai, Sue served as vice president of regulatory affairs at TransMolecular, Inc. where her role also included strategic planning and IP management for its oncology programs. She previously served as vice president of regulatory affairs for Genzyme Corporation, and in parallel was a director for MG Biotherapeutics, a joint venture of Medtronic Inc. and Genzyme. While at Genzyme, Sue was the regulatory lead on novel drug development collaborations with Diacrin, Inc., Cambridge Antibody Technologies and Dyax, Inc. Her commercial product experience includes global registration and life-cycle management of Renagel®, Synvisc®, Carticel® and Thyrogen®. Prior to joining Genzyme, she served as quality assurance supervisor for Abbot Laboratories.
Sue holds a B.A. from Annhurst College and is a fellow of the Regulatory Affairs Professionals Society (FRAPS) and is both U.S. and European Union Regulatory Affairs Certified (RAC).
